Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by DnB Asset Management AS

DnB Asset Management AS boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 246,285 shares of the medical equipment provider's stock after purchasing an additional 35,662 shares during the period. DnB Asset Management AS owned approximately 0.11% of Hologic worth $17,755,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. General Partner Inc. purchased a new stake in shares of Hologic during the fourth quarter worth approximately $26,000. Groupama Asset Managment raised its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Hologic Stock Performance

HOLX stock traded down $0.57 during midday trading on Wednesday, reaching $60.81. The company had a trading volume of 414,222 shares, compared to its average volume of 1,805,662. The firm has a market capitalization of $13.65 billion, a PE ratio of 19.18, a P/E/G ratio of 2.14 and a beta of 0.97. The stock has a 50 day moving average price of $64.90 and a 200 day moving average price of $72.97. Hologic, Inc. has a fifty-two week low of $60.04 and a fifty-two week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of recent analyst reports. BNP Paribas raised Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Wolfe Research assumed coverage on shares of Hologic in a report on Friday, December 13th. They set a "peer perform" rating on the stock. Raymond James restated an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reduced their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Hologic has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.